This prospective observational study will assess the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in clinical practice in patients with chronic kidney disease, in pre-dialysis or on dialysis, initiated on Mircera treatment. Data from each patient will be collected over 12 months of treatment.
Study Type
OBSERVATIONAL
Enrollment
250
Unnamed facility
Tirana, Albania
Achievement of target hemoglobin (Hb) range of 10-12 g/dL according to Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines
Time frame: 2 years
Maintenance of target Hb range (10-12 g/dL)
Time frame: 2 years
Safety: Incidence of adverse events
Time frame: 2 years
Correlation between baseline clinical variables and time on target Hb level
Time frame: 2 years
Dosing pattern in clinical practice, including dose adaptations
Time frame: 2 years
Frequency of visits and laboratory assessments
Time frame: 2 years
Effect of compliance to treatment on Hb levels
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.